- Oracle enhances Randomization and Trial Supply Management (RTSM) with new drug pooling features and multi-vendor integration.
- Built on Oracle Cloud Infrastructure, RTSM now supports end-to-end automation and centralized analytics for drug supply management.
- Integration with vendors like SAP, Almac, and Catalent aims to streamline clinical trial operations, reducing inefficiencies and accelerating timelines.
Oracle Corporation (ORCL, Financial) has announced significant improvements to its Randomization and Trial Supply Management (RTSM) solution. The advancements introduce drug pooling and interoperability features, allowing pharmaceutical companies to manage drug inventory across multiple clinical trials effectively. This update is built on Oracle Cloud Infrastructure and is designed to automate drug supply management end-to-end.
The system now supports integrated supply management with key industry vendors, including SAP, Almac, Fisher Clinical Services, Catalent, and PMD. This integration facilitates the management of investigational products across various trials simultaneously, aiming to reduce inefficiencies and minimize drug waste. By ensuring that the right drug reaches the correct site at the right time, Oracle's RTSM solution seeks to streamline operations and accelerate clinical trial timelines.
The updated RTSM solution includes built-in analytics, providing centralized monitoring of inventory levels, shipment statuses, and drug usage across different trial portfolios. These capabilities are set to appeal to large pharmaceutical companies managing complex development programs.
Oracle's strategic enhancements in the RTSM align with its broader goal of creating an intelligent, continuously learning ecosystem by integrating life sciences applications with electronic health records. This approach aims to reduce costs, improve patient outcomes, and strengthen Oracle's competitive position in the clinical trials software market, estimated to be over $10 billion.
With more than 20 years of experience in the life sciences sector, Oracle remains committed to supporting clinical development and delivering innovations through its comprehensive cloud technology and pharmaceutical research solutions.
